NextCure presents preclinical findings for LNCB74 and new clinical biomarker results for the NC410 combination at the Society for Immunotherapy of Cancer Annual Meeting.

Casimersen, developed by Sarepta Therapeutics, is an antisense oligonucleotide (AON) designed to target and skip exon 45 of the dystrophin gene.

Dupixent has been authorized in the EU as the first and sole treatment for young children suffering from eosinophilic esophagitis.

Iptacopan is a small molecule drug that targets the complement factor B (CFB) and has been approved for various therapeutic areas.

Hanmi Introduces New Obesity Treatment ‘HM17321’: A Breakthrough in Addressing Muscle Loss Linked to GLP-1.

Avastin, also known as bevacizumab, is a monoclonal antibody developed by Genentech, a subsidiary of Roche.

Minghui Pharmaceutical Reports Positive Early Findings from Phase I Trial of MHB039A, a New Bispecific Antibody Targeting PD-1 and VEGF.

CC-91633 is a novel molecular glue drug that targets CK1α and falls within the therapeutic areas of neoplasms, hemic and lymphatic diseases.

Arcus Biosciences reports that the combination of Domvanalimab and Zimberelimab enhanced overall survival in the ARC-10 trial involving patients with high PD-L1 NSCLC.

Bepirovirsen, developed by GSK in collaboration with Ionis Pharmaceuticals, is an antisense oligonucleotide that targets the hepatitis B virus (HBV) RNA.

OSE Immunotherapeutics reports noteworthy and statistically significant findings from the Phase 2 trial of Lusvertikimab, an anti-IL7R monoclonal antibody.

Daprodustat is a small molecule drug developed by GSK Plc which primarily targets Hypoxia-Inducible Factor-Prolyl Hydroxylase (HIF-PH) enzymes.